Plasmocytoid variant urothelial carcinoma (PVUC) of the urinary bladder is a rare histological variant of transitional cell carcinoma. Data regarding PVUC shows that this neoplasia presents a distinctive clinical outcome represented by aggressive behavior and poor survival rate. The authors report a case of a 57-year-old male patient with a 3-month history of hematuria and pelvic pain. Radical cystectomy with lymphadenectomy was performed and pathological examination showed a pT3pN0 PVUC of the bladder. The patient remained free of recurrence for 8 months, but the disease recurred involving the abdominal wall and subcutaneous tissue. Chemotherapy provided a positive clinical response and relief of symptoms. The authors call attention to the aggressiveness of this rare variant of bladder cancer and recommend radical surgery and multidisciplinary management of this neoplasm.
SahinAA, MyhreM, RoJY, SneigeN, DekmezianRH, AyalaAG. Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma. Acta Cytol. 1991;35(3):277-80. [PMID:1710402].
KeckB, StoehrR, WachS, et al. The plasmacytoid carcinoma of the bladder—rare variant of aggressive urothelial carcinoma. Int J Cancer. 2011;129(2):346-54. [https://doi.org/10.1002/ijc.25700]. [PMID:20878954]
DayyaniF, CzerniakBA, SircarK, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189(5):1656-61. [https://doi.org/10.1016/j.juro.2012.11.084]. [PMID:23159581]
RaspolliniMR, SardiI, GiuntiL, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. Hum Pathol. 2011;42(8):1149-58. [https://doi.org/10.1016/j.humpath.2010.11.011]. [PMID:21334719]
ErdemirF, OzcanF, KilicaslanI, ParlaktasBS, UluocakN, GokceO. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol. 2007;39(4):1031-7. [https://doi.org/10.1007/s11255-006-9159-5]. [PMID:17340210]
PanerGP, AnnaiahC, GulmannC, et al. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol. 2014;45(7):1473-82. [https://doi.org/10.1016/j.humpath.2014.02.024]. [PMID:24780825]
KaimakliotisHZ, MonnMF, ChengL, et al. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology. 2014;83(5):1112-6. [https://doi.org/10.1016/j.urology.2013.12.035]. [PMID:24582117]
LoehrerPJSr, EinhornLH, ElsonPJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066-73. [PMID:1607913].